Abstract: The present disclosure relates to modified anti-TNF? polypeptides, compositions comprising modified anti-TNF? polypeptides, methods of making the same, and methods of using the modified anti-TNF? polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of inflammatory disorders using the modified anti-TNF? polypeptides.

Abstract: The present disclosure relates to modified anti-PD-1 polypeptides linked to IL-7, pharmaceutical compositions comprising modified anti-PD-1 polypeptides linked to IL-7, methods of making anti-PD-1 polypeptides linked to IL-7, and methods of using the modified anti-PD-1 polypeptides linked to IL-7 for treatment of diseases. In one aspect, the disclosure relates to methods of treating cancer in a subject using the modified anti-PD-1 polypeptides linked to IL-7. Also provided herein is synthetic IL-7 and methods of manufacture thereof.

Abstract: The present disclosure relates to modified IL-2 polypeptides, compositions comprising modified IL-2 polypeptides, methods of making the same, and methods of using the modified IL-2 polypeptides for treatment of diseases including autoimmune diseases. In one aspect, the disclosure relates to the treatment of autoimmune diseases using the modified IL-2 polypeptides. In some embodiments, the disclosed IL-2 polypeptides exhibit enhanced binding to IL-2 receptor ? and/or reduced binding to IL-2 receptor ?. In another aspect, the modified IL-2 polypeptides exhibit enhanced ability to activate T regulatory cells compared to T effector cells.

Abstract: The present disclosure relates to modified anti-PD-1 polypeptides, pharmaceutical compositions comprising modified anti-PD-1 polypeptides, methods of making anti-PD-1 polypeptides, and methods of using the modified anti-PD-1 polypeptides for treatment of diseases. In one aspect, the disclosure relates to methods of treating cancer in a subject using the modified anti-PD-1 polypeptides.

Abstract: The present disclosure relates to conjugate compositions comprising an antibody or an antigen binding fragment, a synthetic protein, and a linker. The disclosure further relates to methods of making the conjugate compositions and to methods of using the conjugate compositions for the treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the conjugate compositions.

Abstract: The present disclosure relates to modified anti-TNF? polypeptides, compositions comprising modified anti-TNF? polypeptides, methods of making the same, and methods of using the modified anti-TNF? polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of inflammatory disorders using the modified anti-TNF? polypeptides.